Business
TME Pharma to raise €500k through new bond issue and receives new notice of shareholding
BERLIN, August 25, 2025--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases, is pleased to announce that financial capacity will be improved through a new fund raise of €500,000 following on the May 2025 fundraise of €1.7M. The improved financial situation should strengthen TME Pharma's position in discussions with financial and strategic partners. It would also ena
About this update from Tme Pharma N.v.
[{"type":"list","items":[{"val":[{"type":"text","content":"TME Pharma is raising additional funds to accelerate the Company's fundamental activities and to increase its budget for its treasury investment strategy","length":157,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"TME Pharma has secured binding commitments for a new fund raising of a net amount of €500,000 in the form of regular bonds repayable in cash with a 9-month maturity","length":164,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Private, non-listed warrants attached with an exercise price of €0.11, a 2,12% premium to the prior 10-day VWAP, could bring another €702,576 if exercised","length":154,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Lead investor in May financing round has committed to investing a further €427,000 as part of this round","length":104,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The lead investor informed the Company that it currently holds 2.5 million TME Pharma shares through market purchases made since May 2025, and that by exercising all warrants received as part of the May financing and this current financing, such stake could increase to over 10%","length":278,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"TME Pharma CEO, Diede van den Ouden, and Chairman of the Supervisory Board, Maurizio PetitBon, also committed to participate in this round of financing","length":151,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":1008,"olType":false},{"type":"text","content":"BERLIN, August 25, 2025--(BUSINESS WIRE)--Regulatory News:","length":58,"tagName":"p"},{"type":"text","content":"TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases, is pleased to announce that financial capacity will be improved through a new fund raise of €500,000 following on the May 2025 fundraise of €1.7M. The improved financial situation should strengthen TME Pharma's position in discussions with financial and strategic partners. It would also enable the Company to prepare for the future investments recently communicated by TME Pharma and about which the Company will continue to inform shareholders.","length":617,"tagName":"p"},{"type":"text","content":""I’m pl...